16th Mar 2015 08:15
LONDON (Alliance News) - Premaitha Health PLC said Monday it has inked a deal with Esperite NV to allow Espirite's Swiss subsidiary Genoma to have a right to use Premaitha's IONA test for its non-invasive prenatal testing services.
The IONA test is used to estimate the risk of a fetus having Down's syndrome, Edward's syndrome and Patau's syndrome by analysing cell-free fetal DNA from a sample of the mothers blood.
"The completion of this agreement so soon after receiving our CE mark is also a major achievement. We hope this will be the first of many agreements for the IONA test and we look forward to a strong and fruitful partnership with Genoma," said Chief Executive Officer Stephen Little in a statement.
Shares in Premaitha are trading up 12.6% at 30.95 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Premaitha Health